GLP-1 and Alcohol-Related Behaviors: Insights From Preclinical Studies.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical animal studies
PubMed 42461204 · doi:10.1016/j.biopsych.2026.04.022
What was done
This narrative review synthesized preclinical animal research evaluating the effects of short-acting (exenatide/exendin-4) and long-acting (liraglutide, dulaglutide, semaglutide) GLP-1 receptor agonists on alcohol-related behaviors, including intake, motivation, relapse-like behavior, and reward pathways.
What was found
The abstract reports no numerical data, effect sizes, or study counts. Qualitatively, systemic exendin-4 reduced alcohol intake, motivation, and relapse-like behavior in male animals, and long-acting agonists reduced alcohol consummatory behaviors in male and female animals. Both agonist types attenuated alcohol-induced locomotor stimulation, nucleus accumbens dopamine release, and conditioned place preference in male mice.
Why it matters
These findings provide mechanistic support for investigating GLP-1 receptor agonists as potential pharmacological treatments for alcohol use disorder.
Limits
The findings are restricted to animal models and lack human clinical data. The abstract provides no quantitative metrics or search criteria. Confounding physiological side effects, such as nausea, altered gastric emptying, and elevated stress, may also explain the observed reductions in alcohol consumption.
Cited by
- supports Animal studies, small trials, and opportunistic epidemiological studies show a pattern of semaglutide reducing alcohol consumption.